Related Experiment Video
Updated: Aug 28, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study
Tania Delgado Ballestero1, Sonia Escalante Arroyo2,3, Marcos Alfredo Mandrá Noya2,3
1Neurology Department, Consorci Corporació Sanitària Parc Taulí, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain.
Abstract:
Background/Objectives: On-demand therapies are crucial to manage OFF episodes in Parkinson's disease (PD). Inhaled levodopa is a rapid and non-invasive treatment option, but data on its real-world use and patient-reported experience remain limited. This study characterized clinical use patterns and patient experience with inhaled levodopa in routine clinical practice. Methods: We conducted a multicenter, cross-sectional, observational study including patients with PD treated with inhaled levodopa in two Spanish centers. Data on treatment use, patient-reported clinical response, and satisfaction were collected during a single study visit using study-specific questionnaires. Results: Thirty-five patients were included (mean age 70.6 years; 51.4% women). Most patients used inhaled levodopa once daily (51.4%), with administration patterns varying between on-demand (51.4%), fixed (31.4%), and combined regimens (17.1%). According to routine clinical assessments, 80.0% of patients reported a clinical response to inhaled levodopa, with a mean time to onset of 17.7 min and a mean duration of effect of 122.1 min. The perceived response was rated as moderate or marked in 62.8% of patients and was reported to last until the next scheduled oral levodopa dose in 45.7% of patients. Participants highlighted symptom improvement, ease of identifying the appropriate timing of administration, and a favorable perception of treatment safety. Conclusions: In routine clinical practice, inhaled levodopa was associated with a high patient-reported clinical response and favorable treatment experience across diverse patient profiles. These findings provide relevant insights into the real-world use of inhaled levodopa as an on-demand therapy for OFF episodes in PD. Given the exploratory nature of this study, confirmation in larger prospective studies using validated instruments and objective clinical measures is warranted.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Inhaled Medications
Parkinson's Disease: Overview
Direct-Acting Cholinergic Agonists: Therapeutic Uses
